Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Barinthus Biotherapeutics (BRNS)
NASDAQ:BRNS
RESEARCH TOOLSreports
Holding BRNS?
Track your performance easily
BRNS Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$0.81 - $4.16
Previous Close$0.89
Volume142.28K
Average Volume (3M)42.77K
Market Cap
$35.38M
Enterprise Value$48.21M
Total Cash (Recent Filing)$0.00
Total Debt (Recent Filing)$12.67M
Price to Earnings (P/E)―
Beta0.69
Next Earnings
Mar 21, 2025EPS Estimate
-$0.46Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.49
Shares Outstanding40,228,456
10 Day Avg. Volume81,077
30 Day Avg. Volume42,774
Standard Deviation0.19
R-Squared0.02
Alpha-0.03
Financial Highlights & Ratios
Price to Book (P/B)0.23
Price to Sales (P/S)2.39
Price to Cash Flow (P/CF)-0.50
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/Revenue3.22
Enterprise Value/Gross Profit60.12
Enterprise Value/Ebitda-0.89
Forecast
1Y Price Target
$5.00Price Target Upside458.85% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering1
Barinthus Biotherapeutics News
PremiumCompany Announcements
Barinthus Biotherapeutics Reports Promising IM-PROVE II Trial Results
Ownership Overview
3.65%
Insiders
0.03% Mutual Funds
24.29% Other Institutional Investors
72.02% Public Companies and
Individual Investors
Risk Analysis
Main Risk Category
Finance & CorporateFinancial and accounting risks. Risks related to the execution of corporate activity and strategy
BRNS FAQ
What was Barinthus Biotherapeutics’s price range in the past 12 months?
Barinthus Biotherapeutics lowest stock price was $0.81 and its highest was $4.16 in the past 12 months.
What is Barinthus Biotherapeutics’s market cap?
Currently, no data Available
When is Barinthus Biotherapeutics’s upcoming earnings report date?
Barinthus Biotherapeutics’s upcoming earnings report date is Mar 21, 2025 which is in 118 days.
How were Barinthus Biotherapeutics’s earnings last quarter?
Barinthus Biotherapeutics released its earnings results on Nov 06, 2024. The company reported -$0.21 earnings per share for the quarter, beating the consensus estimate of -$0.443 by $0.233.
Is Barinthus Biotherapeutics overvalued?
According to Wall Street analysts Barinthus Biotherapeutics’s price is currently Undervalued.
Does Barinthus Biotherapeutics pay dividends?
Barinthus Biotherapeutics does not currently pay dividends.
What is Barinthus Biotherapeutics’s EPS estimate?
Barinthus Biotherapeutics’s EPS estimate is -$0.46.
How many shares outstanding does Barinthus Biotherapeutics have?
Barinthus Biotherapeutics has 39,033,157 shares outstanding.
What happened to Barinthus Biotherapeutics’s price movement after its last earnings report?
Barinthus Biotherapeutics reported an EPS of -$0.21 in its last earnings report, beating expectations of -$0.443. Following the earnings report the stock price went up 10.448%.
Which hedge fund is a major shareholder of Barinthus Biotherapeutics?
Currently, no hedge funds are holding shares in BRNS
---
Barinthus Biotherapeutics Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$5.00 (458.85% Upside)
$5.00 (458.85% Upside)
Crowd Wisdom
Very Negative
Last 7 Days ▼ 1.9%
Last 30 Days ▼ 0.7%
Last 30 Days ▼ 0.7%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-69.69%
12-Months-Change
Fundamentals
Return on Equity
-32.74%
Trailing 12-Months
Asset Growth
-17.95%
Trailing 12-Months
Company Description
Barinthus Biotherapeutics
Vaccitech PLC is a clinical-stage biopharmaceutical company engaged in the discovery and development of novel immunotherapeutics and vaccines for the treatment and prevention of infectious diseases and cancer. Its therapeutic programs include VTP-300, VTP-200, VTP-850, and VTP-600. Its current prophylactic programs include VTP-400. In addition, it also co-invented a COVID-19 vaccine candidate with the University of Oxford known as COVID-19 Vaccine AstraZeneca.
---
BRNS Stock 12 Month Forecast
Average Price Target
$5.00
▲(458.85% Upside)
Technical Analysis
Best Analysts Covering BRNS
1 Year
1 Year Success Rate
2/18 ratings generated profit
1 Year Average Return
-34.57%
reiterated a buy rating 6 days ago
Copying Yi Chen's trades and holding each position for 1 Year would result in 11.11% of your transactions generating a profit, with an average return of -34.57% per trade.
---